Kurebayashi J, Ishida T, Higashi Y, Suemasu K, Nomoto C, Yoshida K
Second Department of Surgery, Gunma University School of Medicine, Maebashi.
Jpn J Clin Oncol. 1990 Sep;20(3):271-80.
Both estrogen and progesterone receptors have been determined in 613 primary breast cancer patients treated by radical mastectomy. At the cut-off value of 5 fentomoles (fmol) cytosol protein/mg for both receptors, patients with estrogen or progesterone receptor-positive breast cancer showed significantly favorable disease-free, overall and post-recurrence survival curves to those of receptor-negative breast cancer patients. In the patient subgroups: premenopausal, stage III, more than four positive lymph node metastases, postoperative adjuvant tamoxifen therapy, a significantly favorable prognosis was recognized in either estrogen or progesterone receptor-positive patients. Both receptors are thought to be useful prognostic indicators for patients with advanced tumors or for those receiving postoperative adjuvant tamoxifen therapy. When the cut-off value was changed, the maximum significant difference in prognosis between receptor-positive and receptor-negative patients was observed at 5 fmol cytosol protein/mg for the estrogen receptor or 10 fmol/mg cytosol protein for the progesterone receptor. A more detailed examination should be made on the cut-off values of both receptors.
对613例接受根治性乳房切除术的原发性乳腺癌患者测定了雌激素受体和孕激素受体。在两种受体的胞浆蛋白均为5飞摩尔（fmol）/毫克的临界值时，雌激素或孕激素受体阳性的乳腺癌患者与受体阴性的乳腺癌患者相比，其无病生存期、总生存期和复发后生存期曲线均显著更优。在患者亚组中：绝经前、III期、四个以上阳性淋巴结转移、术后辅助他莫昔芬治疗，雌激素或孕激素受体阳性的患者均有显著更优的预后。两种受体均被认为是晚期肿瘤患者或接受术后辅助他莫昔芬治疗患者的有用预后指标。当临界值改变时，雌激素受体为5 fmol胞浆蛋白/毫克或孕激素受体为10 fmol/毫克胞浆蛋白时，受体阳性和受体阴性患者之间的预后最大显著差异被观察到。应对两种受体的临界值进行更详细的研究。
